On August 20, WUXI BIO rose 6.16% in regular trading, reaching HK$49.64 per share with turnover of HK$386 million, hitting a 52-week high. The rally was driven by multiple catalysts including the upcoming board meeting on August 25 to review interim results, with the market holding positive expectations for earnings delivery.

On the sector front, peer WuXi AppTec reported first-half revenue of RMB 28.897 billion, up 38.93% year-over-year, and raised its full-year guidance across all segments, continuously boosting CXO sector sentiment. Additionally, the company recently announced the sale of its 51.1% stake in Borgloon to optimize capital allocation and sharpen focus on its core CRDMO business, a strategic move that has gained market recognition.

Within the Life Sciences Tools and Services sector, the overall performance was robust. Among individual stocks, XTALPI up 11.2%, GENSCRIPT BIO up 10.9%, INSILICO up 7.97%, WUXI APPTEC up 2.18%, and WUXI XDC up 1.4%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)